Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Encorafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 24,191Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination
    FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination

    26 Feb 2026

    // FDA

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-encorafenib-metastatic-colorectal-cancer-braf-v600e-mutation

    FDA
    26 Feb 2026
    Share Share
    FDA Approves Pfizer's BRAFTOVI for First-Line mCRC Treatment
    FDA Approves Pfizer's BRAFTOVI for First-Line mCRC Treatment

    25 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-24/us-fda-grants-full-approval-to-pfizer-s-braftovi-combination-regimen-in-first-line-metastatic-colo

    PHARMIWEB
    25 Feb 2026
    Share Share
    Guardant Health Gets FDA Nod For Guardant360 CDx With BRAFTOVI
    Guardant Health Gets FDA Nod For Guardant360 CDx With BRAFTOVI

    22 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260122091904/en/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    22 Jan 2026
    Share Share
    Pfizer's Braftovi+Mektovi Demonstrates Prolonged Survival
    Pfizer's Braftovi+Mektovi Demonstrates Prolonged Survival

    22 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/pfizers-braftovimektovi-shows-sustained-long-term-survival-in-patients-with-advanced-lung-cancer-18042

    INDPHARMAPOST
    22 Oct 2025
    Share Share
    Pfizer's Braftovi + Mektovi Sustain Long-Term Survival in Cancer
    Pfizer's Braftovi + Mektovi Sustain Long-Term Survival in Cancer

    19 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-19/pfizer-s-braftovi-plus-mektovi-shows-sustained-long-term-survival-in-patients-with-advanced-lung-canc

    PHARMIWEB
    19 Oct 2025
    Share Share
    Pfizer’s Braftovi Combo Halves Death Risk In Colorectal Cancer
    Pfizer’s Braftovi Combo Halves Death Risk In Colorectal Cancer

    30 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250530872619/en/Pfizers-BRAFTOVI-Combination-Regimen-Cuts-the-Risk-of-Death-in-Half-for-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    30 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.